Trial Profile

Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MRNA-4359 (Primary) ; Pembrolizumab (Primary)
Indications Advanced breast cancer; Basal cell cancer; Bladder cancer; Carcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Moderna Therapeutics

Most Recent Events

06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology
13 Sep 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com